Zydus Life Science opened higher at ₹1,136.10, compared with its previous close of ₹1,134.40. During today's session, the stock has traded between ₹1,112.30 and ₹1,139.80, with an average traded price of ₹1,129.10. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Zydus Life Science is now worth
₹ 20,918.00
giving a profit of
₹ 10,918.00 (109.18%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-1.90 (-0.17%)
Day High
₹1,139.80
Day Low
₹1,112.30
Day Open
₹1,136.10
Prev Close
₹1,134.40
Volume
11,13,783
Value Traded
₹125.76 Cr
1W Return
-0.57%
1M Return
1.20%
3M Return
-1.59%
6M Return
23.72%
1Y Return
14.00%
Market Cap (₹ Cr.)
1,12,967
PE Ratio
24.70
PB Ratio
4.19
Dividend Yield
0.09%
ROE
16.99%
ROCE
19.24%
Book Value (₹)
271.78
Face Value (₹)
1.00
EPS (TTM)
9.35
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-0.57%
6 Week
-
1 Month
1.20%
3 Month
-1.59%
9 Month
26.53%
Zydus Therapeutics presents Phase 3 saroglitazar data at ACG 2026
Composite biochemical response rate reached 60.7% in US subgroup vs 0% for placebo. Treatment difference in US subgroup was Δ 60.7%, higher than Δ 41.6% in non-US subgroup. Saroglitazar received FDA Priority Review and Fast Track Designation for PBC treatment. Launch in the United States is planned for March 2027 if regulatory approval is granted.
YesterdayZydus Lifesciences extends JV closing with Sunshine Healthcare to Dec 2026
Zydus Lifesciences and Sunshine Healthcare Lanka extend JV closing to December 2026. Extension due to pending completion of condition precedents in the SSSHA. Joint venture entity is ZyduS Sunshine Lifesciences (Private) Limited. Original intimation regarding the deal was made on June 26, 2026.
12 days agoZydus Lifesciences USFDA inspection ends with one observation
USFDA cGMP inspection at Zydus' Ahmedabad SEZ II plant concluded with one observation. No data integrity related observations were recorded during the September 21-28 inspection. Company plans to address the single observation expeditiously with USFDA.
15 days agoZydus Lifesciences reports nil observations in USFDA pharmacovigilance inspection
USFDA inspected Zydus Lifesciences' New Jersey office from September 22 to September 25, 2026. Inspection focused on pharmacovigilance and post-marketing surveillance systems. Audit concluded with nil observations, indicating no major deficiencies. Disclosure made under SEBI Listing Obligations and Disclosure Requirements.
17 days agoZydus Lifesciences to participate in J.P. Morgan India Conference on September 21
Zydus Lifesciences to present at J.P. Morgan India Conference 2026. The event is scheduled for September 21, 2026. Regulatory filings submitted to BSE and NSE confirm the participation.
1mo agoZydus Lifesciences holds 31st AGM on August 11, 2026
Zydus Lifesciences held its 31st AGM via video conference on August 11, 2026. The meeting lasted from 10:00 am to 11:16 am IST. Chairman Pankaj R. Patel and MD Sharvil P. Patel attended. Statutory auditors from Deloitte Haskins & Sells LLP were present. Proceedings were recorded and posted on the company website.
1mo ago| Contract | Days to Expiry | LTP | Change | Change % | Volume | OI | OI Chg % |
|---|---|---|---|---|---|---|---|
| ZYDUSLIFE OCT FUT | 15 | 1,135.90 | 1.10 | 0.10 | 14,97,600 | 1,05,90,300 | 1.91 |
| ZYDUSLIFE NOV FUT | 42 | 1,141.20 | 0.90 | 0.08 | 1,60,200 | 4,13,100 | 19.22 |
| ZYDUSLIFE DEC FUT | 78 | 1,147.80 | 2.10 | 0.18 | 16,200 | 48,600 | 3.85 |
| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% | |
| ₹351.00 | +1.34% | ₹57,202.26 | 134.86 | -0.69% |
An investment of ₹10,000 made 5 years ago in Zydus Life Science is now worth
₹ 20,918.00
giving a profit of
₹ 10,918.00 (109.18%)
Note: Past profits do not guarantee future returns.
